AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA®, a Fully Human Anti-TNFα Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa | News Release:2020

  • Home
  • News Release
  • 2020 Release
  • AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA®, a Fully Human Anti-TNFα Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa


More:  Eisai Rated “A”, the highest rating in the CDP Climate Change Report 2019 | News Release:2020

More from: | Category: Pharmaceutical Company News